MAGE-1 (230-238)

MAGE-1 (230-238) is a synthetic peptide corresponding to amino acids 230 through 238 of the Melanoma Antigen Gene-1 (MAGE-1) protein, a member of the MAGE family known for its restricted expression in various tumor types and immunological relevance. As a defined peptide fragment, it serves as a valuable tool in immunological research, particularly in the study of antigen processing and presentation, as well as in the development of T-cell based assays. Its sequence specificity and established role in tumor immunology make it a critical reagent for laboratories investigating cancer-associated antigens, immune recognition, and peptide-MHC interactions.

Epitope mapping: The peptide is extensively utilized in epitope mapping studies to delineate T-cell recognition sites within the MAGE-1 protein. By incorporating this sequence into functional assays, researchers can identify and characterize cytotoxic T lymphocyte (CTL) responses specific to the MAGE-1 antigen. Such mapping is fundamental for understanding antigenic determinants involved in immune surveillance and for designing experimental immunotherapeutic strategies targeting tumor-associated antigens.

Antigen presentation studies: MAGE-1 (230-238) is frequently employed to investigate the molecular mechanisms underlying antigen processing and presentation via major histocompatibility complex (MHC) class I molecules. Utilizing this peptide in cellular assays allows for the assessment of peptide binding affinity, stability of peptide-MHC complexes, and the efficiency of presentation to CD8+ T cells. These studies are crucial for elucidating the pathways by which tumor antigens are displayed to the immune system and for optimizing antigen delivery in experimental settings.

T-cell activation assays: The defined sequence of this peptide enables its use as a positive control or experimental variable in T-cell activation assays. By pulsing antigen-presenting cells with the peptide, researchers can monitor T-cell proliferation, cytokine secretion, and cytolytic activity, thereby evaluating the functional capacity of T-cell populations to recognize and respond to MAGE-1-derived epitopes. This application supports the development of in vitro models for cancer immunology and facilitates the screening of T-cell receptor specificity.

Peptide-MHC binding analysis: The sequence is also instrumental in in vitro binding assays designed to assess its interaction with various human leukocyte antigen (HLA) alleles. Quantitative and qualitative studies of peptide-HLA binding inform the selection of immunogenic peptides for research purposes, support the development of peptide-based immunoassays, and enhance the understanding of allele-specific immune responses. Such analyses contribute to the rational design of peptide-based reagents for immunological research.

Synthetic peptide validation: As a well-characterized fragment, MAGE-1 (230-238) is commonly used as a reference standard in the validation of peptide synthesis protocols and analytical methods. Inclusion of this peptide in quality control workflows enables researchers to benchmark synthetic efficiency, assess purity profiles, and calibrate analytical instrumentation. Its use as a validation standard helps ensure reproducibility and reliability in peptide production and downstream experimental applications.

1. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

3. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

5. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation